Expert Interview
A second look: Discussing the label of Cytokinetics' Myqorzo (Aficamten) and how it may fare commercially vs Camzyos (Mavacamten) in oHCM
Ticker(s): CYTK, BMYInstitution: Baylor University College of Medicine
- Interventional Cardiologist, Associate Professor, and Chief of Cardiology at Baylor College of Medicine.
- Treats ~75 patients with pulmonary arterial hypertension.
- Studies the molecular mechanisms of cardiovascular development with a focus on the intrinsic signaling that trigger cardiac regeneration early in life, molecular events that regulate developmental decisions instructing cardiac progenitor cells to adopt a specific cell fate, and delivery approaches of cardiovascular progenitors into an injured heart.
- Recently identified several novel surface markers that can highly enrich for early cardiovascular progenitors and his studies have established the basis for future PSC-based cardiac therapy.
On a scale from 1-10 (10 being extremely excited), where would you rate your level of excitement for Aficamten as a treatment for oHCM?
Added By: wilson_adminHow significant are label differences vs Camzyos?
Added By: wilson_adminWhat % of new starts do you think would be on Myqorzo over Camzyos?
Added By: wilson_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
